

81527_Auto_Edited.docx

7

Name of Journal: *World Journal of Gastrointestinal Oncology*

Manuscript NO: 81527

Manuscript Type: ORIGINAL ARTICLE

Retrospective Study

1

Survival benefits and disparities in radiation therapy for elderly patients with pancreatic ductal adenocarcinoma

Cao BY *et al.* Radiation therapy for elderly PDAC

Bi-Yang Cao, Qian-Qian Wang, Le-Tian Zhang, Chen-Chen Wu, Fang Tong, Wei Yang, Jing Wang

Abstract

BACKGROUND

Older patients represent a unique subgroup of the cancer patient population, for which the role of cancer therapy requires special consideration. The effects of radiation therapy (RT) on the outcomes of elderly patients with pancreatic ductal adenocarcinoma (PDAC) are not well-defined in the literature.

AIM

To explore the use and effectiveness of RT in the treatment of elderly patients with PDAC in clinical practice.

METHODS

Data from patients with PDAC aged ≥ 65 years between 2004 and 2018 were collected from the Surveillance, Epidemiology, and End Results database. Multivariate logistic regression analysis was performed to determine factors associated with RT administration. Overall survival (OS) and cancer-specific survival (CSS) were evaluated using the Kaplan-Meier method with the log-rank test. Univariate and multivariate analyses with the Cox proportional hazards model were used to identify prognostic factors for OS. Propensity score matching (PSM) was applied to balance the baseline characteristics between the RT and non-RT groups. Subgroup analyses were performed based on clinical characteristics.

RESULTS

A total of 12245 patients met the inclusion criteria, with 2551 (20.8%) patients treated with RT and 9694 (79.2%) who were not. The odds of receiving RT increased with younger age, diagnosis in an earlier period, primary site in the head, localized disease, greater tumor size, and chemotherapy (all $p < 0.05$). Before PSM, the RT group had better outcomes than did the non-RT group (median OS, 14.0 vs. 6.0 mo; hazard ratio (HR) for OS, 0.862, 95% confidence interval (CI), 0.819–0.908, $p < 0.001$; and HR for CSS, 0.867,

95%CI, 0.823–0.914, $p<0.001$). After PSM, the survival benefit associated with RT remained comparable (median OS, 14.0 vs. 11.0 mo; HR for OS, 0.818, 95%CI, 0.768–0.872, $p<0.001$; and HR for CSS, 0.816, 95%CI, 0.765–0.871, $p<0.001$). Subgroup analysis revealed that the survival benefits (OS and CSS) of RT were more significant in patients aged 65 to 80 years, in regional and distant stages, with no surgery, and receiving chemotherapy.

CONCLUSION

RT improves the outcome of elderly patients with PDAC, particularly those aged 65 to 80 years, in regional and distant stages, with no surgery, and receiving chemotherapy. Prospective studies are warranted to validate our results.

Key Words: Pancreatic ductal adenocarcinoma; Elderly; Radiotherapy; Effectiveness; Disparities; SEER.

Cao BY, Wang QQ, Zhang LT, Wu CC, Tong F, Yang W, Wang J. ¹Survival benefits and disparities in radiation therapy for elderly patients with pancreatic ductal adenocarcinoma. *World J Gastrointest Oncol* 2022; In press

²**Core Tip:** Older patients represent a unique subgroup of the cancer patient population, for which the role of cancer therapy requires special consideration. ¹The effects of radiation therapy (RT) on the outcomes of elderly patients with pancreatic ductal adenocarcinoma (PDAC) are not well-defined in the literature. Herein, data were extracted from the Surveillance, Epidemiology, and End Results (SEER) database to ¹identify factors associated with RT administration and explore the impact of RT on survival in elderly PDAC patients. ¹This study highlights the survival benefit of RT in elderly patients with PDAC on a larger population scale and proposes possible obstacles to accessing treatment for elderly patients with PDAC.

INTRODUCTION

Pancreatic ductal adenocarcinoma (PDAC) is the 12th most common malignancy and the seventh most common cause of cancer-related deaths worldwide^[1]. The incidence of PDAC increases with age and is more common in older adults. The number of elderly individuals with PDAC will increase as lifespans increase, according to the World Health Organization (WHO)^[2]. Approximately 70% of cancers, including PDAC, are diagnosed in adults over 65 years by 2030^[3].

Surgery is the only treatment option for this disease; however, only 10–20% of patients are eligible for surgical resection^[4]. Elderly patients with PDAC are frequently debilitated at baseline because of poor nutrition, pain, and jaundice, along with other symptoms; consequently, the majority of this population is medically inoperable or refuses to undergo surgery. Furthermore, intensive chemotherapy cannot be tolerated by some elderly patients due to their poor performance status; for these individuals, radiation therapy (RT) is considered a treatment option with a variety of goals (definitive, neoadjuvant, adjuvant, or palliative)^[5]. Recent advancements in computational modeling and medical imaging have enabled more precise treatment administration and decreased toxicity^[6]. These advancements are expected to continue to accelerate following a "double-exponential" growth pattern in coming years. Recently, RT has become an increasingly popular nonsurgical treatment for multiple types of cancer in the elderly^[7-9].

Elderly patients, defined by the WHO as those older than 65, represent a unique patient population for whom anticancer treatment requires special consideration. This population is under-represented in clinical trials, however, because of co-existing comorbid illnesses^[10, 11]. The management of these conditions largely remains unknown and is primarily extrapolated from younger patients with many retrospective experiences but low sample sizes. There are no randomized studies on the utilization of RT in elderly patients with PDAC, and the survival impact of RT in these patients has not yet been clarified.

To further investigate the survival benefits and disparities in RT for elderly patients with PDAC, data from the SEER database was used to identify factors associated with RT administration and to explore the impact of RT on survival in PDAC patients over 65 years old. This study highlights the survival benefit of RT in elderly patients with PDAC on a larger population scale and proposes possible obstacles to accessing treatment for elderly patients with PDAC.

MATERIALS AND METHODS

Population Selection

PDAC cases were identified as those pathologically diagnosed between 2004 and 2018 as having primary malignant tumors of the pancreas using the International Classification of Diseases for Oncology, Third Edition (ICD-O-3) histology codes 8140 and 8500 from the SEER program of the National Cancer Institute. The inclusion criteria were as follows: (1) age over 65 years, (2) a pathologic diagnosis of PDAC, and (3) a diagnosis of PDAC between 2004 and 2018. Samples were excluded based on the following criteria: (1) diagnosis at autopsy or *via* death certificates, (2) cancer-specific death classification was missing, (3) survival time was unknown or was less than one month, (4) non-primary tumor or more than one primary tumor present, (5) the receipt information of radiation was unknown, and (6) the follow-up information was unknown or information on demographic and clinical characteristics was incomplete. The detailed selection process for the inclusion of patients is shown in **Figure 1**. All patient data in this study were collected from the SEER database using SEER*Stat v8.3.8 software (seer.cancer.gov/seerstat). The SEER Research Plus Data Agreement was signed and a license to analyze the study data was obtained in November 2021 (username: 15159-Nov2020).

Variables and Definition of Endpoint

Demographic, clinicopathological, and therapeutic information was extracted along with survival information. The demographic characteristics included age at diagnosis, sex, race, year of diagnosis, and marital status. The clinicopathological features included

the primary tumor site, SEER stage, tumor size, node status, and histological grade. Treatment patterns included surgery at the primary site, radiotherapy, and chemotherapy. The survival information included survival months, survival months flag, vital status, and cancer-specific death classification. Patients were classified by age at diagnosis into two groups: 65-80 years or >80 years, based on previous studies^[12, 13] and our clinical practice. Tumor size was divided into three groups according to the T classification of the American Joint Committee on Cancer 8th edition (<2 cm, 2-4 cm, or >4 cm). Diagnoses between 2004 and 2010 were considered the former period, and those from 2010 to 2018 were defined as the latter period. SEER stages were divided into localized-, regional-, or distant-stage diseases.

The primary endpoint was overall survival (OS), and the secondary endpoint was cancer-specific survival (CSS). OS was defined as the time interval from the first PDAC diagnosis to death for any reason or the last follow-up. CSS was defined as the time interval from the diagnosis of PDAC to PDAC-related death or the last follow-up. Follow-up was started at the time of diagnosis, and all enrolled patients were effectively followed up. The final follow-up was on November 31, 2018.

Statistical Analysis

The patients were divided into RT and non-RT groups. All categorical variables were represented as frequencies with percentages (%) and compared using the chi-square test. Propensity score matching (PSM) was performed to minimize the effects of potential confounding factors. All baseline characteristics were included except for the utilization of RT in the propensity score model to maximally inform the propensity of the dependent variable. The variables included age at diagnosis, sex, race, year of diagnosis, marital status, primary site, SEER stage, tumor size, node status, histology grade, surgery to the primary site, and chemotherapy. Propensity scores were estimated using logistic regression modeling, with the receipt of RT as the dependent variable. In a nearest-neighbor matching algorithm without replacement, patients who received RT and those who did not were matched 1:1 using a caliper size of 0.05 times the standard

deviation of the propensity. PSM was performed using the “Matchit” R package in R software (version 4.0.1, The R Foundation for Statistical Computing).

Univariate and multivariate logistic regression analyses were performed to identify the factors associated with RT administration. Univariate and multivariate analyses of OS and CSS were conducted using Cox proportional hazard regression before and after PSM. The covariates that had a $P < 0.05$ in the univariate analysis were selected for further multivariate analysis. Survival curves were estimated using the Kaplan-Meier method and compared using the log-rank test. Subgroup analyses were performed using univariate Cox regression. All statistical analyses were conducted using R software (version 4.0.1; <http://www.r-project.org>). A two-tailed P value of <0.05 was considered statistically significant.

RESULTS

Patient Characteristics

Between January 2004 and December 2018, 20690 patients aged ≥ 65 years with PDAC were identified in the SEER database. In total, 12245 patients met the inclusion and exclusion criteria for the study. The patients were separated into two groups based on whether they underwent RT or not. Before PSM, there were 2551 cases of RT and 9694 cases of non-RT; after PSM, there were 2250 cases in both groups. **Table 1** summarizes the demographic and clinical features of patients before and after PSM. Before PSM, in comparison to the non-RT group, the RT group contained more younger, female, and married patients, had a higher proportion of patients with a primary site in the head, a higher proportion of patients with well or moderately differentiated tumors, a higher percentage of patients with positive node status and larger tumors (2–4 cm), and patients were more likely to undergo surgery and chemotherapy. After PSM, all baseline covariates were well-balanced between the RT and non-RT groups (**Table 1**).

Factors Associated with Receiving RT

In a logistic regression model evaluating the factors associated with RT receipt (Table 2), greater tumor size and chemotherapy were associated with RT therapy, while older age, later period of diagnosis, a primary site in the body or tail, and distant disease were associated with RT not being administered. Patients aged 80 years and older had a significantly lower likelihood of receiving RT [odds ratio (OR) 0.84, 95% confidence interval (CI), 0.74–0.97; $P = 0.014$]. Patients between 2011 and 2018 had a lower likelihood of receiving RT (OR 0.47, 95%CI, 0.42–0.52; $p < 0.001$), as did patients with a primary site in the body or tail (OR 0.87, 95%CI, 0.77–0.99; $P = 0.032$). Patients between 2011 and 2018 were less likely to receive RT (OR 0.47, 95%CI, 0.42–0.52; $p < 0.001$), as were patients with a primary site in the body or tail (OR 0.87, 95%CI, 0.77–0.99; $P = 0.032$). RT was less likely to be administered to patients with distant metastasis (OR 0.17, 95%CI, 0.14–0.21, $p < 0.001$). Patients who had received chemotherapy were more likely to receive RT (OR 7.05, 95%CI, 6.14–8.10, $p < 0.001$). The likelihood of receiving RT did not differ according to sex, race, marital status, histological grade, node status, or surgery.

Survival Outcomes

Before PSM, the median OS was 14.0 mo (95%CI, 13.5–14.5 mo) in the RT group and 6.0 mo (95%CI, 5.8–6.2 mo) in the non-RT group. The 5-year OS rates were 8.34% (95%CI, 7.20%–9.67%) and 4.16% (95%CI, 3.70%–4.68%), respectively, for the RT and non-RT groups ($p < 0.0001$) (Figure 2(A)). The median CSS was 14.0 mo (95%CI, 13.4–14.6 mo) in the non-RT group and 6.0 mo (95%CI, 5.8–6.2 mo) in the non-RT group. The 5-year CSS rates were 9.26% (95%CI, 8.02%–10.70%) and 5.01% (95%CI, 4.48%–5.60%), respectively, in the RT and non-RT groups. ($p < 0.0001$) (Figure 2(B)). RT still significantly improved survival after PSM. The median OS for the two groups was 14.0 mo (95%CI, 13.4–14.6 mo) and 11.0 mo (95%CI, 10.4–11.6 mo), respectively, and the 5-year OS rates were 8.1% (95%CI, 31.9%–51.4%) and 7.3% (95%CI, 14.5%–30.5%), respectively, for the RT and non-RT groups ($p < 0.0001$) (Figure 3(A)). The median CSS was 14.0 mo (95%CI, 13.4–14.6 mo) and 11.0 mo (95%CI, 10.4–11.6 mo), respectively,

and the 5-year CSS rates were 9.10% (95%CI, 7.76%–10.70%) and 8.62% (95%CI, 7.33%–10.10%), respectively, for the RT and non-RT groups ($p < 0.0001$) (**Figure 3(B)**).

1 Prognostic Factors

After PSM, univariate analysis revealed that RT, age, year of diagnosis, marital status, primary site, histological grade, SEER stage, node status, tumor size, surgery at the primary site, and chemotherapy were all significantly associated with OS and CSS. Other variables had no effect on OS or CSS in elderly patients with PDAC. In multivariable analysis, RT, histological grade, SEER stage, node status, tumor size, surgery at the primary site, and chemotherapy were all statistically significant. RT was found to be an independent predictor of both OS (hazard ratio [HR]: 0.818, 95%CI, 0.768–0.872, $p < 0.001$) and CSS (HR: 0.816, 95%CI, 0.765–0.871, $p < 0.001$) (**Table 3**). The results of univariate and multivariate analyses based on unmatched data were consistent with those predicted from matched data, except that race was identified as an independent prognostic factor both in OS and CSS (**Supplemental Table 1**).

Subgroup analysis

To assess the effect of RT in the subpopulations, in addition to the main analysis, subgroup analyses before and after PSM were performed. Before PSM, RT benefited patients in all subgroups, except RT which failed to significantly improve OS ($P = 0.092$) and CSS ($P = 0.215$) in patients with localized disease. The HRs and associated CIs from all subgroup analyses are graphically summarized in forest plots in **Supplementary Figures 1 and 2**. After PSM, as shown in the forest plots displayed in **Figures 4 and 5**, the results of the subgroup analysis demonstrated that RT had a significant OS and CSS advantage in the majority of subgroups. Given that age, stage, and treatment patterns are critical independent risk factors for survival, the results of these subgroups in particular were highlighted. For age, clinical benefits from RT could be seen in the population aged 65 to 80 years (Age 65–80, OS: HR, 0.83; 95%CI, 0.77–0.89; $p < 0.001$; CSS: HR, 0.82; 95%CI, 0.77–0.88; $p < 0.001$; Age >80, OS: HR, 1.03; 95%CI, 0.89–1.20; $P = 0.681$; CSS: HR, 1.05; 95%CI, 0.90–1.23; $P = 0.51$). The elderly population with PDAC was a highly heterogeneous group with all stages of disease, and there were huge

1 differences in the role of RT in this group. Because of this, the effect of RT on the survival of the matched cohort at specific stages was explored. RT brought a significant OS and CSS advantage for the regional-stage and distant-stage patients (regional-stage, OS: HR, 0.82; 95%CI, 0.76–0.89; $p < 0.001$; CSS: HR, 0.82; 95%CI, 0.76–0.89; $p < 0.001$; distant-stage, OS: HR, 0.70; 95%CI, 0.61–0.81; $p < 0.001$; CSS: HR, 0.69; 95%CI, 0.60–0.80; $p < 0.001$); in contrast, no significant survival difference was found between the non-RT and RT groups in localized-stage patients (localized-stage, OS: HR, 1.10; 95%CI, 0.92–1.32; $P = 0.28$; CSS: HR, 1.13; 95%CI, 0.94–1.37; $P = 0.15$). As for treatment patterns, RT improved OS and CSS for patients who had no surgery (surgery, OS: HR, 0.94; 95%CI, 0.84–1.06; $P = 0.323$; CSS: HR, 0.95; 95%CI, 0.84–1.07; $P = 0.37$; no surgery, OS: HR, 0.79; 95%CI, 0.73–0.85; $p < 0.001$; HR, 0.79; 95%CI, 0.73–0.85; $p < 0.001$) or received chemotherapy (chemotherapy, OS: HR, 0.83; 95%CI, 0.77–0.89; $p < 0.001$; CSS: 0.83; 95%CI, 0.77–0.89; $p < 0.001$; no chemotherapy, OS: HR, 0.97; 95%CI, 0.82–1.15; $P = 0.734$; HR, 1.00; 95%CI, 0.84–1.19; $P = 0.98$).

DISCUSSION

This study found a survival benefit in elderly patients who received RT for PDAC, using patient data from the SEER database with a relatively large sample size. We showed that elderly PDAC patients who were treated with RT had longer median OS and CSS outcomes than patients who did not receive RT. Before PSM, it was found that the RT group had superior OS (median OS: 14.0 mo vs. 6.0 mo, $p < 0.0001$) and CSS (median CSS: 14.0 mo vs. 6.0 mo, $p < 0.0001$) 1 with an 8-month median survival advantage over the non-RT group. After PSM, the RT group remained to outperform the non-RT group in terms of OS (median OS: 14.0 mo vs. 11.0 mo, $p < 0.0001$) and CSS (median CSS: 14.0 mo vs. 11.0 mo, $p < 0.0001$). 1 Receiving RT still resulted in a 3-month increase in the median survival time. Furthermore, we performed multivariate Cox regression analyses in order 1 to determine the independent impact of RT on survival. Before PSM, it was found that the RT group had superior OS (HR, 0.862; 95%CI, 0.819–0.908, $p < 0.001$) and CSS (HR, 0.867; 95%CI, 0.823–0.914, $p < 0.001$) with

lower mortality rate over the non-RT group. After PSM, the RT group consistently performed better than the non-RT group in terms of OS (HR, 0.818; 95%CI, 0.768–0.872, $p<0.001$) and CSS (HR, 0.816; 95%CI, 0.765–0.871, $p<0.001$). Above results in the multivariate analysis, after excluding potential confounding factors, indicate that elderly PDAC patients have improved survival after receiving RT. Studies evaluating the use of RT in PDAC have been reviewed and discussed in the context of treating older patients^[14-23]; Table 4 summarizes the characteristics and outcomes of these findings. The results of these studies indicate that RT appears to be tolerable in older patients and can be considered a viable treatment option for PDAC in this population, further confirming the conclusions of our study.

In addition, lower histological grade, early SEER stage, negative node status, smaller tumor size, surgery at the primary site, and receiving chemotherapy were identified as independent favorable prognostic predictors for OS and CSS of elderly PDAC patients in the matched population. As we all know, histological grade, tumor stage, node status and tumor size are histological and biological characteristics of the malignant neoplasms, which were confirmed as prognostic features for OS in multiple malignancies, including PDAC^[24-26]. Our results were consistent with previous studies^[12, 23, 27]. Previous studies suggested that older patients are less likely than younger patients to accept or be prescribed surgical treatment that might extend their life. Our study demonstrated that resection of the primary tumor could prolong survival in elderly patients with PDAC. A SEER database analysis revealed that elderly patients with PDAC who underwent cancer-directed surgical procedures had a higher survival rate than the non-surgery group^[28]. In recent years, with more methods to optimize pancreatic cancer surgery using Warshaw technology and minimally invasive surgery, cancer-directed surgical treatment options were recommended for carefully selected elderly PDAC patients^[4]. Chemotherapy was the most common form of treatment for PDAC, which applies to elderly patients with PDAC as well. Resection followed by with or without radiation is the standard treatment for resectable PDAC patients^[29, 30]. For locally advanced unresectable and metastatic PDAC, chemotherapy

remains the mainstay of treatment^[31, 32]. Our study confirmed an overall survival benefit of chemotherapy in the elderly patients with PDAC.

We performed subgroup analysis and discovered that most subgroups could benefit from RT, notably those aged 65 to 80 years, diagnosed in latter period, with regional or distant disease, tumor size of 2 to 4cm or greater than 4cm, no surgery, and receiving chemotherapy. Subgroup analysis stratified by age at diagnosis reveals that RT may be beneficial for older patients, particularly those aged 65 to 80 years. This could be because patients aged 65 to 80 years have a higher tolerance for radiation therapy and are in better general physical condition for consequential treatment than those beyond 80 years^[33]. Patients with PDAC are frequently incapacitated at the outset due to malnutrition, discomfort, jaundice, or other symptoms. Only 20% of patients with surgically resectable disease receive radical surgery for cure^[34]. Elderly individuals are more likely to require inpatient nursing home care after surgery and have a higher surgical mortality rate^[35], even though high-volume facilities and less invasive procedures can enhance outcomes. A subset of older individuals who are deemed ineligible for surgery or refuse surgery due to poor performance status or comorbidities are treated with definitive chemoradiation in clinical. Thus, in the current study, patients who did not have surgery or those received chemotherapy were more likely to benefit from RT. Similarly, patients with regional disease were more prone to have involvement or direct extension invasion of peripheral organs and major vessels, and also a lower chance of undergoing curative surgery, resulting in a greater benefit from RT in subgroups of regional disease. For patients with metastatic disease, the role of RT in achieving local control and symptom relief has been established by current guidelines, including the management of obstruction, pain resistant to analgesics, or bleeding^[5]. Furthermore, we discovered that patients with larger tumors benefited more from RT than those with smaller tumors. One probable explanation is that patients with larger tumors were more likely to present with involvement or direct extension invasion to peripheral organs and major arteries, and were more likely to get definitive radiation or chemoradiotherapy. Patients diagnosed in the latter era benefited

significantly more from RT than those diagnosed in the former. This could be attributed to the growing implementation of more modern radiation treatments, thus improving the protection of organs at risk (OAR) and decreasing side effects [6].

The elderly are a distinct subgroup of cancer patients, for whom the role of RT requires special consideration. To our knowledge, this is the first population-based analysis utilizing PSM to assess the survival benefits of RT in older patients with PDAC. In this study, both multivariate regression and propensity score-matched analyses showed that RT could improve survival in PDAC patients over 65 years of age. The favorable effect on survival found in the comprehensive SEER database highlights the necessity of RT in the treatment of elderly PDAC patients. Based on these findings, older individuals should not reject RT only because of clinical concerns about toxicity, as RT may be a viable therapeutic choice for PDAC even in elderly patients. Further research and trials with older patients are required to determine the benefit ratio for various therapy scenarios.

This study has several limitations. First, even when using the propensity score matching approach to balance the baseline, selection bias in the retrospective analysis may not be eliminated due to unmeasured confounders, as with any other observational study. Second, in the SEER database, treatment is defined as being used during the first course of cancer-directed therapy without detailed data about chemotherapy and the dose or duration of RT; thus, the current study aimed to qualitatively and quantitatively describe the role of RT in elderly PDAC patients. Incorporating additional information on chemotherapy, RT, and treatment modalities would be advantageous for investigating the effects of RT on survival in elderly patients with PDAC. Investigation of the impact of the type, dose, timing, intent, or method used in RT for elderly patients with PDAC may also be aided by data from randomized clinical trials.

CONCLUSION

In summary, the current study demonstrated that elderly PDAC patients who were treated with RT had improved OS and CSS compared with patients who were not

1 treated with RT. This study adds to the growing literature on retrospective studies of the role of RT in elderly patients with PDAC and highlights the need for a large multicenter randomized trial to further understand this subject.

ARTICLE HIGHLIGHTS

Research background

8
2 Pancreatic ductal adenocarcinoma (PDAC) is primarily a disease of the elderly, with a median age of diagnosis of 70 years. Elderly patients represent a unique subgroup of the cancer patient population, for which the role of cancer therapy requires special consideration.

Research motivation

2 Radiation therapy (RT) plays an evolving and pivotal role in providing optimal care for PDAC. However, studies evaluating the use and effectiveness of RT on PDAC in the older patient population are scarce.

Research objectives

To explore the use and effectiveness of RT in the treatment of elderly patients with PDAC in clinical practice.

Research methods

6 Data from patients with PDAC aged ≥ 65 years between 2004 and 2018 were collected from the Surveillance, Epidemiology, and End Results database. Multivariate logistic regression analysis was performed to determine factors associated with RT administration. Overall survival (OS) and cancer-specific survival (CSS) were evaluated using the Kaplan-Meier method with the log-rank test. Univariate and multivariate analyses with the Cox proportional hazards model were used to identify prognostic factors for OS. Propensity score matching (PSM) was applied to balance the baseline

characteristics between the RT and non-RT groups. Subgroup analyses were performed based on clinical characteristics.

Research results

A total of 12245 patients met the inclusion criteria, with 2551 (20.8%) patients treated with RT and 9694 (79.2%) who were not. The odds of receiving RT increased with younger age, diagnosis in an earlier period, primary site in the head, localized disease, greater tumor size, and chemotherapy (all $p < 0.05$). Before PSM, the RT group had better outcomes than did the non-RT group (median OS, 14.0 vs. 6.0 mo; hazard ratio (HR) for OS, 0.862, 95% confidence interval (CI), 0.819–0.908, $p < 0.001$; and HR for CSS, 0.867, 95%CI, 0.823–0.914, $p < 0.001$). After PSM, the survival benefit associated with RT remained comparable (median OS, 14.0 vs. 11.0 mo; HR for OS, 0.818, 95%CI, 0.768–0.872, $p < 0.001$; and HR for CSS, 0.816, 95%CI, 0.765–0.871, $p < 0.001$). Subgroup analysis revealed that the survival benefits (OS and CSS) of RT were more significant in patients aged 65 to 80 years, in regional and distant stages, with no surgery, and receiving chemotherapy.

Research conclusions

The current study demonstrated that elderly PDAC patients who were treated with RT had improved OS and CSS compared with patients who were not treated with RT

Research perspectives

This study adds to the growing literature on retrospective studies of the role of RT in elderly patients with PDAC and highlights the need for a large multicenter randomized trial to further understand this subject.

ACKNOWLEDGEMENTS

The authors sincerely appreciate the efforts of the Surveillance, Epidemiology, and End Results (SEER) Program tumor registries in establishing the SEER database.



49%

SIMILARITY INDEX

PRIMARY SOURCES

1	www.researchsquare.com Internet	2189 words — 45%
2	www.pubfacts.com Internet	51 words — 1%
3	Ammoren Dohm, Roberto Diaz, Ronica H. Nanda. "The Role of Radiation Therapy in the Older Patient", Current Oncology Reports, 2021 Crossref	38 words — 1%
4	journals.lww.com Internet	24 words — < 1%
5	www.hindawi.com Internet	21 words — < 1%
6	www.journaltoics.ac.uk Internet	16 words — < 1%
7	f6publishing.blob.core.windows.net Internet	15 words — < 1%
8	www.ncbi.nlm.nih.gov Internet	15 words — < 1%
9	eventscribe.com Internet	12 words — < 1%

EXCLUDE QUOTES	ON	EXCLUDE SOURCES	< 12 WORDS
EXCLUDE BIBLIOGRAPHY	ON	EXCLUDE MATCHES	< 12 WORDS